Glycosaminoglycans in the pathogenesis and diagnostics of Graves's ophthalmopathy;Glikozaminoglikany w patogenezie i diagnostyce oftalmopatii Gravesa

Postepy Higieny i Medycyny Doswiadczalnej

Volumn 60, Issue , 2006, Pages 370-378

  Daroszewski, Jacek ^a   Rybka, Jacek ^b   Gamian, Andrzej ^b  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

^b INSTITUTE OF IMMUNOLOGY AND EXPERIMENTAL THERAPY   (Poland)

Author keywords

Glycosaminogycans; Graves's disease; Ophthalmopathy

Indexed keywords

GLYCOSAMINOGLYCAN;

ENDOCRINE OPHTHALMOPATHY; HUMAN; METABOLISM; PATHOPHYSIOLOGY; REVIEW;

ENGLISH ABSTRACT; GLYCOSAMINOGLYCANS; GRAVES OPHTHALMOPATHY; HUMANS;

EID: 33846060835     PISSN: 00325449     EISSN: 17322693     Source Type: Journal    
DOI: None     Document Type: Review

References (75)

1. Bahn R.S.: Clinical review 157: Pathophysiology of Graves' ophthalmopathy: The cycle of disease. J. Clin. Endocrinol. Metab., 2003; 88, 1939-1946
2. Bahn R.S., Heufelder A.E.: Pathogenesis of Graves' ophthalmopathy. N. Engl. J. Med., 1993; 329, 1468-1475
3. Barry F.: Proteoglycans: structure and function. Biochem. Soc. Trans., 1990; 18, 197-198
4. Berenson C.S., Smith T.J.: Human orbital fibroblasts in culture express ganglioside profiles distinct from those in dermal fibroblasts. J. Clin. Endocrinol. Metab., 1995; 80, 2668-2674
5. Bitter T., Muir H.M.: A modified uronic acid carbazole reaction. Anal. Biochem., 1962; 4, 330-334
6. Borrello M.A., Phipps R.P.: Differential Thy-1 expression by splenic fibroblasts defines functionally distinct subsets. Cell Immunol., 1996; 173, 198-206
7. Burch H.B., Wartofsky L.: Graves' ophthalmopathy: current concepts regarding pathogenesis and management. Endocr. Rev., 1993; 14, 747-793
8. Chang T.C., Yao W.C., Chang C.C.: Octreotide and urinary glycosaminoglycan in Graves' disease. BMJ, 1992; 304, 1444
9. Daroszewski J.: Metody oceny aktywnosci oftalmopatii endokrynnej. Terapia, 2001; 2, 30-32
10. Daroszewski J., Bolanowski M., Gamian A., Rybka J., Spring A.: The use of glycosaminoglycan excretion measurements in the assessment of the organic complications in acromegaly. Pol. J. Endocrinol., 2001; 52, 347-352
11. Daroszewski J., Pelczar E., Bolanowski M., Gamian A., Rybka J.: Glycosaminoglycans urine excretion as a predictor of therapeutic outcome in Graves' ophtalmopathy patients. Abstract Book 11th International Congress of Endocrinology, Sydney, 29.10.-02.11.2000, 2000
12. Daroszewski J., Pelczar E., Bolanowski M., Gamian A., Rybka J.: Glycosaminoglycanes excretion and serum IL-6 levels in the endocrine ophtalmopathy patients treated with pentoxyfilline and methylprednisolone. Adv. Clin. Exp. Med., 2004; 13, 35-39
13. Daroszewski J., Pelczar E., Bolanowski M., Rybka J., Gamian A.: Serum hyaluronic acid as a predictor of the outcome of the treatment of Graves' ophthalmopathy. Proceedings of European Congress of Endocrinology, Goeteborg, 2005; P2-124
14. Daroszewski J., Pelczar E., Grabiñski M., Gamian A., Rybka J.: Glycosaminoglycans urine excretion as a marker of the acute phase of Graves' ophtalmopathy. J. Endocrinol. Invest., 1997; 20(Supl.5): 94
15. de Jong J.G., Wevers R.A., Laarakkers C., Poorthuis B.J.: Dimethylmethylene blue-based spectrophotometry of glycosaminoglycans in untreated urine: A rapid screening procedure for mucopolysaccharidoses. Clin. Chem., 1989; 35, 1472-1477
16. Feldon S.E., Park D.J., O'Loughlin C.W., Nguyen V.T., Landskroner-Eiger S., Chang D., Thatcher T.H., Phipps R.P.: Autologous T-lymphocytes stimulate proliferation of orbital fibroblasts derived from patients with Graves' ophthalmopathy. Invest Ophthalmol. Vis. Sci., 2005; 46, 3913-3921
17. Fieber C., Baumann P., Vallon R., Termeer C., Simon J.C., Hofmann M., Angel P., Herrlich P., Sleeman J.P.: Hyaluronan-oligosaccharide-induced transcription of metalloproteases. J. Cell Sci., 2004; 117, 359-367
18. Fries K.M., Blieden T., Looney R.J., Sempowski G.D., Silvera M.R., Willis R.A., Phipps R.P.: Evidence of fibroblast heterogeneity and the role of fibroblast subpopulations in fibrosis. Clin. Immunol. Immunopathol., 1994; 72, 283-292
19. Gayno J.P. Strauch G.: Ciclosporine and Graves' ophthalmopathy. Horm. Res., 1987; 26, 190-197
20. Glatz C.E., Massaro T.A.: Influence of glycosaminoglycan content on mass transfer behavior of porcine artery wall. Part 2. Differences in mass transfer rates related to variations in glycosaminoglycan content. Atherosclerosis, 1976; 25, 165-173
21. Glinoer D., Etienne-Decerf J., Schrooyen M., Sand G., Hoyoux P., Mahieu P., Winand R.: Beneficial effects of intensive plasma exchange followed by immunosuppressive therapy in severe Graves' ophthalmopathy. Acta Endocrinol. (Copenh.), 1986; 111, 30-38
22. Glowacki A., Koma E. M., Olczyk K., Kucharz E.J.: Glikozoaminoglikany-struktura i funkcja. Post. Biochem., 1995; 41, 139-148
23. Hall C.L., Wang C., Lange L.A., Turley E.A.: Hyaluronan and the hyaluronan receptor RHAMM promote focal adhesion turnover and transient tyrosine kinase activity. J. Cell Biol., 1994; 126, 575-588
24. Hansen C., Rouhi R., Forster G., Kahaly G.J.: Increased sulfatation of orbital glycosaminoglycans in Graves' ophthalmopathy. J. Clin. Endocrinol. Metab., 1999; 84, 1409-1413
25. Heufelder A.E., Bahn R.S., Boergen K.P., Scriba P.C.: Detection, localization and modulation of hyaluronic acid/CD44 receptor expression in patients with endocrine orbitopathy. Med. Klin. (Munich), 1993; 88, 181-184, 277
26. Kaback L.A., Smith T.J.: Expression of hyaluronan synthase messenger ribonucleic acids and their induction by interleukin-1beta in human orbital fibroblasts: potential insight into the molecular pathogenesis of thyroid-associated ophthalmopathy. J. Clin. Endocrinol. Metab., 1999; 84, 4079-4084
27. Kahaly G., Forster G., Hansen C.: Glycosaminoglycans in thyroid eye disease. Thyroid, 1998; 8, 429-432
28. Kahaly G., Hansen C., Stover C., Kuhlemann K., Beyer J., Otto E.: Glycosaminoglycans and Endocrine Orbitopathy. Exp. Clin. Endocrinol., 1994; 102, 151-161
29. Kahaly G., Schuler M., Sewell A.C., Bernhard G., Beyer J., Krause U.: Urinary glycosaminoglycans in Graves' ophthalmopathy. Clin. Endocrinol. (Oxf), 1990; 33, 35-44
30. Kahaly G., Stover C., Otto E., Beyer J., Schuler M.: Glycosaminoglycans in thyroid-associated ophthalmopathy. Autoimmunity, 1992; 13, 81-88
31. Kaznowska-Bystryk I., Chlebus D.: Wydalanie glikozaminoglikanów (GAG) z moczem-znaczenie diagnostyczne. Diagn. Lab., 2000; 36, 93-101
32. Koumas L., King A.E., Critchley H.O., Kelly R.W., Phipps R.P.: Fibroblast heterogeneity: existence of functionally distinct Thy 1(+) and Thy 1(-) human female reproductive tract fibroblasts. Am. J. Pathol., 2001; 159, 925-935
33. Koma E.M., Glowacki A., Olczyk K., Jawiec M.: Proteoglikany-struktura i funkcja. Post. Biochem., 1997; 43, 158-172
34. Kula B., Jurczak T, Przenioslo L, Pawlowska-Góral K., Szade A., Wardas M.: Glikozaminoglikany (GAG)-wlasciwosci, wystêpowanie i funkcja. Ann. Acad. Med. Siles., 1995; 273-281
35. Kung A.W., Michon J., Tai K.S., Chan F.L.: The effect of somatostatin versus corticosteroid in the treatment of Graves' ophthalmopathy. Thyroid, 1996; 6, 381-384
36. Lien E., Means T.K., Heine H., Yoshimura A., Kusumoto S., Fukase K., Fenton M.J., Oikawa M., Qureshi N., Monks B., Finberg R.W., Ingalls R.R., Golenbock D.T.: Toll-like receptor 4 imparts ligand-specific recognition of bacterial lipopolysaccharide. J. Clin. Invest., 2000; 105, 497-504
37. Marcocci C., Bartalena L., Bogazzi F., Bruno-Bossio G., Lepri A., Pinchera A.: Orbital radiotherapy combined with high dose systemic glucocorticoids for Graves' ophthalmopathy is more effective than radiotherapy alone: results of a prospective randomized study. J. Endocrinol. Invest., 1991; 14, 853-860
38. Marino M., Lisi S., Pinchera A., Marcocci C., Menconi F., Morabito E., Macchia M., Sellari-Franceschini S., McCluskey R.T., Chiovato L.: Glycosaminoglycans provide a binding site for thyroglobulin in orbital tissues of patients with thyroid-associated ophthalmopathy. Thyroid, 2003; 13, 851-859
39. Martins J.R., Furlanetto R.P., Oliveira L.M., Mendes A., Passerotti C.C., Chiamolera M.I., Rocha A.J., Manso P.G., Nader H.B., Dietrich C.P., Maciel R.M.: Comparison of practical methods for urinary glycosaminoglycans and serum hyaluronan with clinical activity scores in patients with Graves' ophthalmopathy. Clin. Endocrinol. (Oxf), 2004; 60, 726-733
40. Martins J.R., Passerotti C.C., Maciel R.M., Sampaio L.O., Dietrich C.P., Nader H.B.: Practical determination of hyaluronan by a new noncompetitive fluorescence-based assay on serum of normal and cirrhotic patients. Anal. Biochem., 2003; 319, 65-72
41. Muller G.A. Strutz F.M.: Renal fibroblast heterogeneity. Kidney Int. Suppl., 1995; 50, S33-S36
42. Mullin B.R., Levinson R.E., Friedman A., Henson D.E., Winand R.J., Kohn L.D.: Delayed hypersensitivity in Graves' disease and exophthalmos: identification of thyroglobulin in normal human orbital muscle. Endocrinology, 1977; 100, 351-366
43. Noble P.W., McKee C.M., Cowman M., Shin H.S.: Hyaluronan fragments activate an NF-kappa B/I-kappa B alpha autoregulatory loop in murine macrophages. J. Exp. Med., 1996; 183, 2373-2378
44. O'Brien J.M.: Infections, inflammations, and immune-mediated orbital disease. Curr. Opin. Ophthalmol., 1995; 6, 59-69
45. Perros P. Kendall-Taylor P.: Thyroid-associated ophthalmopathy: pathogenesis and clinical management. Baillieres Clin. Endocrinol. Metab., 1995; 9, 115-135
46. Pilarska K., Kulig G., Krzystolik Z.: Ocena wydalania z moczem glikozoaminoglikanów (GAG) w trakcie leczenia postêpujacej oftalmopatii obrzêkowo-naciekowej w przebiegu choroby Gravesa i Basedowa. Pol. Arch. Med. Wewn., 2001; 105, 139-144
47. Poltorak A., He X., Smirnova I., Liu M.Y., Van Huffel C., Du X., Birdwell D., Alejos E., Silva M., Galanos C., Freudenberg M., Ricciardi-Castagnoli P., Layton B., Beutler B.: Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science, 1998; 282, 2085-2088
48. Poulsen J.H.: Urine and tissue glycosaminoglycans and their interrelations. Dan. Med. Bull., 1986; 33, 75-96
49. Prabhakar B.S., Bahn R.S., Smith T.J.: Current perspective on the pathogenesis of Graves' disease and ophthalmopathy. Endocr. Rev., 2003; 24, 802-835
50. Priestley G.C., Aldridge R.D., Hurel S.: Urinary glycosaminoglycans excretion in Graves' disease. Acta Derm. Venereol., 1996; 76, 368-370
51. Prummel M.F., Mourits M.P., Berghout A., Krenning E.P., van der Gaag R., Koornneef L., Wiersinga W.M.: Prednisone and cyclosporine in the treatment of severe Graves' ophthalmopathy. N. Engl. J. Med., 1989; 321, 1353-1359
52. Prummel M.F., Wiersinga W.M., Mourits M. P.: Assessment of disease activity of Graves' ophtalmopathy. In: Recent developments in Graves' ophtalmopathy. Kluwer Academic Publ. 2000; 59-80
53. Rescigno M., Granucci F., Citterio S., Foti M., Ricciardi-Castagnoli P.: Coordinated events during bacteria-induced DC maturation. Immunol. Today, 1999; 20, 200-203
54. Rock F.L., Hardiman G., Timans J.C., Kastelein R.A., Bazan J.F.: A family of human receptors structurally related to Drosophila Toll. Proc. Natl. Acad. Sci. USA, 1998; 95, 588-593
55. Sciaky D., Brazer W., Center D.M., Cruikshank W.W., Smith T.J.: Cultured human fibroblasts express constitutive IL-16 mRNA: cytokine induction of active IL-16 protein synthesis through a caspase-3-dependent mechanism. J. Immunol., 2000; 164, 3806-3814
56. Sempowski G.D., Beckmann M.P., Derdak S., Phipps R.P.: Subsets of murine lung fibroblasts express membrane-bound and soluble IL-4 receptors. Role of IL-4 in enhancing fibroblast proliferation and collagen synthesis. J. Immunol., 1994; 152, 3606-3614
57. Singh A.P. Nikiforuk M.: Studies in relation to endocrine exophthalmos: The biochemical composition of human retrobulbar connective tissue. Experientia, 1976; 32, 395-396
58. Smith R.S., Smith T.J., Blieden T.M., Phipps R.P.: Fibroblasts as sentinel cells. Synthesis of chemokines and regulation of inflammation. Am. J. Pathol., 1997; 151, 317-322
59. Smith T.J., Bahn R.S., Gorman C.A.: Hormonal regulation of hyaluronate synthesis in cultured human fibroblasts: evidence for differences between retroocular and dermal fibroblasts. J. Clin. Endocrinol. Metab., 1989; 69, 1019-1023
60. Smith T.J., Bahn R.S., Gorman C.A.: Connective tissue, glycosaminoglycans, and diseases of the thyroid. Endocr. Rev., 1989; 10, 366-391
61. Smith T.J., Kottke R.J., Lum H., Andersen T.T.: Human orbital fibroblasts in culture bind and respond to endothelin. Am. J. Physiol., 1993; 265, C138-C142
62. Smith T.J., Koumas L., Gagnon A., Bell A., Sempowski G.D., Phipps R.P., Sorisky A.: Orbital fibroblast heterogeneity may determine the clinical presentation of thyroid-associated ophthalmopathy. J. Clin. Endocrinol. Metab., 2002; 87, 385-392
63. Smith T.J., Wang H.S., Evans C.H.: Leukoregulin is a potent inducer of hyaluronan synthesis in cultured human orbital fibroblasts. Am. J. Physiol., 1995; 268, C382-C388
64. Stamenkovic I., Clark E.A., Seed B.: A B-lymphocyte activation molecule related to the nerve growth factor receptor induced by cytokines in carcinomas. EMBO J., 1989; 8, 1403-1410
65. Starkey K., Heufelder A., Baker G., Joba W., Evans M., Davies S., Ludgate M.: Peroxisome proliferator-activated receptor-gamma in thyroid eye disease: contraindication for thiazolidinedione use? J. Clin. Endocrinol. Metab., 2003; 88, 55-59
66. Takeuchi O., Hoshino K., Kawai T., Sanjo H., Takada H., Ogawa T., Takeda K., Akira S.: Differential roles of TLR2 TLR4 in recognition of gram-negative gram-positive bacterial cell wall components. Immunity, 1999; 11, 443-451
67. Tallstedt L., Norberg R.: Immunohistochemical staining of normal Graves' extraocular muscle. Invest Ophthalmol. Vis. Sci., 1988; 29, 175-184
68. Taylor K.A. Buchanan-Smith J.G.: A colorimetric method for the quantitation of uronic acids a specific assay for galacturonic acid. Anal. Biochem., 1992; 201, 190-196
69. Ursu H., Dumitrescu, C., Bartoc R., Dumitriu L.: Determination of urinary mucopolysaccharides in Graves' disease. Endocrinologie, 1984; 22, 277-282
70. Valyasevi R.W., Erickson D.Z., Harteneck D.A., Dutton C.M., Heufelder A.E., Jyonouchi S.C., Bahn R.S.: Differentiation of human orbital preadipocyte fibroblasts induces expression of functional thyrotropin receptor. J. Clin. Endocrinol. Metab., 1999; 84, 2557-2562
71. Valyasevi R.W., Harteneck D.A., Dutton C.M., Bahn R.S.: Stimulation of adipogenesis, peroxisome proliferator-activated receptor-gamma (PPARgamma), thyrotropin receptor by PPARgamma agonist in human orbital preadipocyte fibroblasts. J. Clin. Endocrinol. Metab., 2002; 87, 2352-2358
72. Varma R. Varma R.S.: Mucopolysaccharides-Glycosaminoglycans-of Body Fluids in Health Disease. 1983
73. Weetman A.P.: Autoimmune thyroid disease. Autoimmunity, 2004; 37, 337-340
74. Wiersinga W.M.: Immunosuppression in endocrine ophthalmopathy: why when? Dev. Ophthalmol., 1993; 25, 120-130
75. Winand R.J.: Increased urinary excretion of acidic mucopolysaccharides in exophthalmos. J. Clin. Incest., 1968; 47, 2563-2568